We are pleased to announce Dr. Bill A. Williams is joining Novoheart today as Senior Vice President, Commercial Operations. With over 20 years of experience as a senior technical sales and business development executive in the biotechnology sector, Dr. Williams comes to Novoheart as a highly influential leader in the life science industry.

Novoheart announced today that a presentation was delivered on June 22nd, 2018, entitled “Modeling Cardiac Dysfunction of Friedreich’s Ataxia Using Ventricular Sheets, Tissues and Chambers Engineered from Human Pluripotent Stem Cells,” at the Annual Meeting of the International Society for Stem Cell Research in Melbourne, Australia. The presentation includes data from research conducted with Pfizer Inc. on a 3D engineered human cardiac tissue disease model of Friedreich’s ataxia (FRDA), a neurodegenerative disease in which patients most often die of heart complications. The new disease model helps capture both electrical and mechanical defects of the heart observed in patients with FRDA.

Novoheart announced today that its MyHeart^TM platform, including the world’s first and only ‘human heart-in-a-jar’, has been selected as 2018’s “Best New Technology Solution – Drug Development” by MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market.

Novoheart Limited, a wholly owned subsidiary of global stem cell biotechnology company, Novoheart Holdings Inc., has been awarded a non-dilutional government grant of C$400,000 from the Innovation and Technology Commission (ITC) of Hong Kong. The grant has been awarded to Novoheart to further enhance the drug screening capabilities of its proprietary human ventricular cardiac tissue strip, as part of its unique MyHeart^TM Platform of bioengineered human heart tissues. Including this latest grant, Novoheart has received close to C$2.2 million R&D funding from the ITC.